首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   3209篇
  免费   121篇
  国内免费   13篇
耳鼻咽喉   41篇
儿科学   38篇
妇产科学   41篇
基础医学   499篇
口腔科学   24篇
临床医学   413篇
内科学   657篇
皮肤病学   29篇
神经病学   282篇
特种医学   131篇
外科学   474篇
综合类   4篇
一般理论   1篇
预防医学   180篇
眼科学   32篇
药学   304篇
中国医学   6篇
肿瘤学   187篇
  2023年   9篇
  2022年   9篇
  2021年   84篇
  2020年   24篇
  2019年   52篇
  2018年   74篇
  2017年   53篇
  2016年   43篇
  2015年   72篇
  2014年   75篇
  2013年   117篇
  2012年   254篇
  2011年   258篇
  2010年   128篇
  2009年   128篇
  2008年   245篇
  2007年   250篇
  2006年   272篇
  2005年   253篇
  2004年   236篇
  2003年   200篇
  2002年   211篇
  2001年   23篇
  2000年   15篇
  1999年   13篇
  1998年   26篇
  1997年   34篇
  1996年   13篇
  1995年   32篇
  1994年   19篇
  1993年   22篇
  1992年   17篇
  1991年   3篇
  1990年   8篇
  1989年   10篇
  1988年   15篇
  1987年   3篇
  1986年   7篇
  1985年   4篇
  1984年   6篇
  1983年   5篇
  1982年   4篇
  1981年   3篇
  1980年   3篇
  1979年   1篇
  1978年   1篇
  1977年   6篇
  1974年   2篇
  1966年   1篇
排序方式: 共有3343条查询结果,搜索用时 31 毫秒
1.
2.
BackgroundTo date, the risk/benefit balance of lockdown in controlling severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) epidemic is controversial.ObjectiveWe aimed to investigate the effectiveness of lockdown on SARS-CoV-2 epidemic progression in nine different countries (New Zealand, France, Spain, Germany, the Netherlands, Italy, the UK, Sweden, and the USA).DesignWe conducted a cross-country comparative evaluation using a susceptible-infected-recovered (SIR)-based model completed with pharmacokinetic approaches.Main MeasuresThe rate of new daily SARS-CoV-2 cases in the nine countries was calculated from the World Health Organization’s published data. Using a SIR-based model, we determined the infection (β) and recovery (γ) rate constants; their corresponding half-lives (t1/2β and t1/2γ); the basic reproduction numbers (R0 as β/γ); the rates of susceptible S(t), infected I(t), and recovered R(t) compartments; and the effectiveness of lockdown. Since this approach requires the epidemic termination to build the (I) compartment, we determined S(t) at an early epidemic stage using simple linear regressions.Key ResultsIn New Zealand, France, Spain, Germany, the Netherlands, Italy, and the UK, early-onset stay-at-home orders and restrictions followed by gradual deconfinement allowed rapid reduction in SARS-CoV-2-infected individuals (t1/2β ≤ 14 days) with R0 ≤ 1.5 and rapid recovery (t1/2γ ≤ 18 days). By contrast, in Sweden (no lockdown) and the USA (heterogeneous state-dependent lockdown followed by abrupt deconfinement scenarios), a prolonged plateau of SARS-CoV-2-infected individuals (terminal t1/2β of 23 and 40 days, respectively) with elevated R0 (4.9 and 4.4, respectively) and non-ending recovery (terminal t1/2γ of 112 and 179 days, respectively) was observed.ConclusionsEarly-onset lockdown with gradual deconfinement allowed shortening the SARS-CoV-2 epidemic and reducing contaminations. Lockdown should be considered as an effective public health intervention to halt epidemic progression.KEY WORDS: COVID-19, epidemic, lockdown, modeling, pharmacokinetics, SARS-CoV-2  相似文献   
3.
4.
5.
6.
7.
The simulation of rarefied gas flows through complex porous media is challenging due to the tortuous flow pathways inherent to such structures. The Lattice Boltzmann method (LBM) has been identified as a promising avenue to solve flows through complex geometries due to the simplicity of its scheme and its high parallel computational efficiency. It has been proposed to model the stress-strain relationship with the extended Navier-Stokes equations rather than attempting to directly solve the Boltzmann equation. However, a regularization technique is required to filter out non-resolved higher-order components with a low-order velocity scheme. Although slip boundary conditions (BCs) have been proposed for the non-regularized multiple relaxation time LBM (MRT-LBM) for planar geometries, previous slip BCs have never been verified extensively with the regularization technique. In this work, following an extensive literature review on the imposition of slip BCs for rarefied flows with the LBM, it is proven that earlier values for kinetic parameters developed to impose slip BCs are inaccurate for the regularized MRT-LBM and differ between the D2Q9 and D3Q15 schemes. The error was eliminated for planar flows and good agreement between analytical solutions for arrays of cylinders and spheres was found with a wide range of Knudsen numbers.  相似文献   
8.
We studied cross-reactive antibodies against avian influenza H5N1 and 2009 pandemic (p) H1N1 in 200 serum samples from US military personnel collected before the H1N1 pandemic. Assays used to measure antibodies against viral proteins involved in protection included a hemagglutination inhibition (HI) assay and a neuraminidase inhibition (NI) assay. Viral neutralization by antibodies against avian influenza H5N1 and 2009 pH1N1 was assessed by influenza (H5) pseudotyped lentiviral particle-based and H1N1 microneutralization assays. Some US military personnel had cross-neutralizing antibodies against H5N1 (14%) and 2009 pH1N1 (16.5%). The odds of having cross-neutralizing antibodies against 2009 pH1N1 were 4.4 times higher in subjects receiving more than five inactivated whole influenza virus vaccinations than those subjects with no record of vaccination. Although unclear if the result of prior vaccination or disease exposure, these pre-existing antibodies may prevent or reduce disease severity.Outbreaks of 1997 avian influenza H5N1 and 2009 pandemic (p) H1N1 in humans have provided an opportunity to gain insight into cross-reactive immunity. The US military periodically collects and stores serum samples from service members linked to medical records.1 We measured cross-reactive antibodies in stored serum to avian influenza H5N1 and 2009 pH1N1 from US military personnel and identified factors associated with presence of neutralizing antibodies.Two hundred archived serum samples were obtained from the US Department of Defense Serum Repository. They were representative of a wide cross-section of active military personnel at the times of collection, whereas specific geographic information was not available on the individual selected; the cohort represents the general US military population, which is deployed throughout the United States and globally. Fifty samples each were selected from four birth cohorts: (1) < 1949, (2) 1960–1965, (3) 1966–1971, and (4) 1972–1977. Within each cohort, 25 samples were collected in the year 2000 (before the introduction of intranasal live attenuated influenza vaccine [LAIV]), and 25 samples were collected in 2008 (where 51% of donors had received LAIV). It has been suggested that LAIV elicits cross-reactive immunity.2,3 The samples were all collected before the outbreak of 2009 pH1N1, and there have not been any reported outbreaks of H5N1 in US military personnel.Assays used to measure antibodies included a hemagglutination inhibition (HI) assay and a neuraminidase inhibition (NI) assay.4 Viral neutralization by antibodies against H5N1 and 2009 pH1N1 was assessed by influenza (H5) pseudotyped lentiviral particle-based (H5pp)5 and microneutralization assays, respectively. Electronic medical and vaccination records from the Defense Medical Surveillance System (DMSS), which captured records before the serum sample date, were linked to samples and compared with the in vitro results.1The odds ratios (ORs) and 95% confidence intervals (95% CIs) of univariate and multivariate binary logistic regression analyses were used to determine the association between donor characteristics and positive antibody responses. A multiple logistic regression model was constructed, and it included independent variables with a P value of < 0.05 in univariate logistic regression. A P value of < 0.05 was considered to indicate statistical significance. SPSS 12.0 for Windows (SPSS Inc., Chicago, IL) was used to perform all statistical analysis.Cross-reactivity is summarized in 5 and 22.5% for the NI assay. H5pp and NI antibody titers to H5N1 were evenly distributed among birth cohorts and did not differ substantially based on history of vaccination or prior respiratory infections. Of those individuals with neutralizing antibodies to H5N1 (N = 28), 32.1% also had neutralizing antibodies to pH1N1, whereas 19.3% of those individuals with any H5N1-specific antibody response also had neutralizing antibodies to pH1N1 (
Characteristics (n)H5N12009 pH1N1§
HI assay* % positive (GM titer)H5pp % positive (GM titer)NI assay % positive (GM titer)HI assay % positive (GM titer)Neutralization % positive (GM titer)NI assay % positive (GM titer)
Total
 2000.5 (5.1)14.0 (21.4)22.5 (121.6)5.5 (7.1)16.5 (20.4)9.0 (92.8)
Birth cohort
 1936–1949 (50)2.0 (5.3)18.0 (22.0)24.0 (126.0)6.0 (7.3)16.0 (19.5)12.0 (97.6)
 1960–1965 (50)0.0 (5.0)16.0 (20.3)26.0 (129.6)6.0 (7.7)30.0 (27.5)6.0 (90.3)
 1966–1971 (50)0.0 (5.0)12.0 (23.3)20.0 (117.9)10.0 (8.0)16.0 (23.6)10.0 (92.2)
 1972–1977 (50)0.0 (5.3)10.0 (20.0)20.0 (113.7)0.0 (5.7)4.0 (13.6)8.0 (91.5)
Serum collection year
 Y2000 (100)0.0 (5.1)15.0 (21.7)21.0 (120.3)7.0 (7.3)16.0 (20.6)11.0 (94.5)
 Y2008 (100)1.0 (5.2)13.0 (21.1)24.0 (123.0)4.0 (7.0)17.0 (20.1)7.0 (91.2)
Sex
 Female (32)3.1 (5.7)21.9 (26.3)12.5 (102.4)3.1 (6.9)12.5 (19.2)6.3 (96.7)
 Male (168)0.0 (5.0)12.5 (20.5)24.4 (125.7)6.0 (7.2)17.3 (20.6)9.5 (92.1)
Any cross-reactive antibody to
 H5N1 (57)8.8 (8.9)19.3 (25.2)22.8 (119.9)
 pH1N1 (45)2.2 (5.3)28.9 (31.2)37.8 (165.2)
Neutralizing antibodies to
 H5N1 H5pp (28)10.7 (9.5)32.1 (33.6)25.0 (116.9)
 2009 pH1N1 neutralization (33)3.0 (5.4)27.3 (28.9)30.3 (140.3)
Lifetime seasonal vaccinations
 No record (66)0.0 (5.1)10.6 (20.2)27.7 (128.1)7.6 (7.4)15.2 (20.6)12.1 (96.5)
 1–5 vaccinations (88)1.1 (5.2)15.9 (21.5)17.0 (109.2)5.7 (7.1)17.0 (20.5)6.8 (89.1)
  > 5 vaccinations (46)0.0 (5.1)15.2 (22.2)32.6 (138.8)2.2 (6.8)17.4 (19.7)8.7 (95.0)
Time since last vaccine
 No record (66)0.0 (5.1)10.6 (20.2)22.7 (128.1)7.6 (7.4)15.2 (20.6)12.1 (96.5)
  ≤ 1 year (96)0.0 (5.1)15.6 (21.5)24.0 (120.7)4.2 (7.1)19.8 (21.0)8.3 (91.2)
 > 1 year (38)2.6 (5.3)15.8 (22.4)18.4 (113.4)5.2 (6.8)10.5 (18.3)5.3 (90.6)
Vaccination history lifetime (at least one dose)
 No record of vaccination (66)0.0 (5.1)10.6 (20.2)22.7 (128.1)7.6 (7.4)15.2 (20.6)12.1 (96.5)
 Inactivated whole virus (71)0.0 (5.0)14.1 (20.4)22.5 (115.7)2.8 (6.4)15.5 (19.6)5.6 (87.1)
 Split type (102)1.0 (5.0)15.7 (20.4)21.6 (115.7)4.9 (6.4)19.6 (19.6)6.9 (87.1)
 Influenza vaccine not otherwise specified (16)0.0 (5.2)12.5 (27.9)37.5 (166.4)0.0 (6.2)6.3 (16.1)12.5 (102.3)
 Live attenuated intranasal (50)0.0 (5.1)10.0 (18.8)20.0 (112.2)4.0 (7.0)18.0 (20.3)4.0 (85.2)
History of respiratory illness
 No record of illness (119)0.0 (5.0)10.1 (18.5)18.5 (112.6)4.2 (7.0)15.1 (20.5)8.4 (90.7)
 Influenza-like illness (4)0.0 (5.0)25.0 (20.7)0.0 (80.0)0.0 (8.4)25.0 (28.3)25.0 (100.2)
 Upper respiratory infection (65)1.5 (5.4)23.1 (29.3)27.7 (135.0)7.7 (7.3)18.5 (20.7)9.2 (93.1)
 Lower respiratory infection (37)2.7 (5.6)18.9 (30.2)35.1 (157.6)8.1 (8.1)21.6 (22.4)13.5 (108.4)
 Respiratory illness past year (28)0 (5.1)25.0 (25.1)32.1 (154.9)7.1 (8.0)28.6 (24.4)3.6 (86.3)
Open in a separate windowTiters with a value of zero (below the detection limit) were assigned a value of five for calculation of geometric means (GMs).*H5N1, A/Vietnam/1203/2004; positive titer ≥ 40.H5 hemagglutinin (A/Cambodia/408008/05) pseudotyped lentiviral particle; positive titer ≥ 160.Reassortant H1N1 (HA, PB1, PB2, PA, NP, and M from H1N1 [A/PR/8/34]; N1 from H5N1 [A/Vietnam/DT-036/2005]); positive titer ≥ 160.§2009 H1N1, A/California/04/2009; same positive titer cutoffs as for H5N1.As with H5N1, samples with positive HI titers were low for 2009 pH1N1 at 5.5%, whereas neutralizing antibody titers were higher, with 16.5% positive in the microneutralization assay but only 9% positive in the NI assay. Positive neutralization titers were less evenly distributed among birth cohorts, with only 4% positive in the 1972–1977 birth cohort, whereas 30% were positive in the 1960–1965 cohort. Like H5N1, positive antibody titers to 2009 pH1N1 did not differ substantially based on history of vaccination or prior respiratory infections. Of those individuals with neutralizing antibodies to pH1N1 (N = 33), 27.3% also had neutralizing antibodies to H5N1, whereas 28.9% of those individuals with any pH1N1-specific antibody response also had neutralizing antibodies to H5N1.Univariate associations between the prevalence of cross-reactive antibodies to H5N1 and 2009 pH1N1 and independent variables, including year of birth, serum collection year, sex, and seasonal influenza vaccination history, are shown in Characteristic (n)2009 pH1N1H5N1PrevalenceOR (95% CI)Adjusted OR (95% CI)PrevalenceOR (95% CI)Positive neutralizing antibody33 (16.5%)28 (14.0%)Serum collection year 2000 (100)16 (16.0%)ReferenceReference15 (15.0%)Reference 2008 (100)17 (17.0%)1.1 (0.5–2.3)0.7 (0.3–1.8)13 (13.0%)0.9 (0.4–1.9)Birth cohort 1936–1949 (50)8 (16.0%)4.6 (0.9–22.7)5.3 (1.0–27.0)9 (18.0%)2.0 (0.6–6.4) 1960–1965 (50)15 (30.0%)10.3 (2.2–47.9)11.0 (2.3–52.9)8 (16.0%)1.7 (0.5–5.7) 1966–1971 (50)8 (16.0%)4.6 (0.9–22.7)5.1 (1.0–26.2)6 (12.0%)1.2 (0.4–4.3) 1972–1977 (50)2 (4.0%)ReferenceReference5 (10.0%)ReferenceSex Female (32)4 (12.5%)Reference7 (21.9%)Reference Male (168)29 (17.3%)1.5 (0.5–4.5)21 (12.5%)0.5 (0.2–1.3)Positive neutralizing antibody titers H5pp (57)11 (19.3%)1.3 (0.6–2.9) pH1N1 (45)13 (28.9%)3.8 (1.6–8.7)Vaccination record Number of seasonal influenza vaccinations  No record (66)10 (15.2%)Reference7 (10.6%)Reference  1–5 vaccinations (88)15 (17.0%)1.2 (0.5–2.8)14 (15.9%)1.6 (0.6–4.2)  > 5 vaccinations (46)8 (17.4%)1.2 (0.4–3.3)7 (15.2%)1.5 (0.5–4.7) Time since last vaccination  No record (66)10 (15.2%)Reference7 (10.61%)Reference   ≤ 1 year (96)19 (19.8%)1.4 (0.6–3.2)15 (15.6%)1.6 (0.6–4.1)  > 1 year (33)4 (10.5%)0.7 (0.2–2.3)6 (15.8%)1.6 (0.5–5.1) Number of inactivated whole virus vaccinations  No record (129)22 (17.1%)ReferenceReference18 (14.0%)Reference  1–5 vaccinations (53)4 (7.5%)0.4 (0.1–1.2)0.4 (0.1–1.4)7 (13.2%)0.9 (0.4–2.4)  > 5 vaccinations (18)7 (38.9%)3.1 (1.1–8.9)4.4 (1.3–15.6)3 (16.7%)1.2 (0.3–4.7) Time since last inactivated whole virus vaccination  No record (129)22 (17.1%)Reference18 (14.0%)Reference   ≤ 1 year (19)4 (21.1%)1.3 (0.4–4.3)3 (15.8%)1.2 (0.3–4.4)  > 1 year (52)7 (13.5%)0.8 (0.3–1.9)7 (13.5%)1.0 (0.4–2.5) Number of split type vaccinations  No record (98)13 (13.3%)Reference12 (12.2%)Reference  1–5 vaccinations (94)19 (20.2%)1.7 (0.8–3.6)14 (14.9%)1.3 (0.6–2.9)  > 5 vaccinations (8)1 (12.5%)0.9 (0.1–8.2)2 (25.0%)2.4 (0.4–13.2) Time since last split type vaccination  No record (98)13 (13.3%)Reference12 (12.2%)Reference   ≤ 1 year (44)10 (22.7%)1.9 (0.8–4.8)10 (22.7%)2.1 (0.8–5.3)  > 1 year (58)10 (17.2%)1.4 (0.6–3.3)6 (10.3%)0.8 (0.3–2.3) Number of intranasal LAIV vaccinations  No record (150)24 (16.0%)Reference23 (15.3%)Reference  1–5 vaccinations (50)9 (18.0%)1.2 (0.5–2.7)5 (10%)0.6 (0.2–1.7) Time since last intranasal LAIV vaccination  No record (150)24 (16.0%)Reference23 (15.3%)Reference   ≤ 1 year (34)7 (20.6%)1.4 (0.5–3.5)3 (8.8%)0.5 (0.2–1.9)  > 1 year (16)2 (12.5%)0.8 (0.2–3.5)2 (12.5%)0.8 (0.2–3.7)Open in a separate windowTo the best of our knowledge, the present study is the first report of cross-reactive antibodies to both H5N1 and 2009 pH1N1 in a US military population. Cross-reactive antibodies to both influenza viruses were common in this population. Most serum samples (86%) positive in the H5N1 neutralization assay had no detectable HI activity (titer ≥ 10), whereas 94% of samples that neutralized 2009 pH1N1 also had detectable HI activity (titer ≥ 10; data not shown). In addition, cross-reactive antibodies to avian influenza H5N1 were not necessarily accompanied by cross-reactive antibodies to 2009 pH1N1. Taken together, these findings suggest that the observed cross-reactive neutralization against the two influenza viruses was caused by different antibodies in serum samples.This report is also the first report to associate history of receiving more than five doses of inactivated whole influenza virus vaccine with neutralizing antibodies against 2009 pH1N1. This finding suggests a protective advantage of repeated vaccination with seasonal whole virus vaccine, generating cross-reactive antibodies against previously unencountered strains. It has been suggested that the high immunogenicity of the inactivated whole virus vaccine is partly caused by the adjuvant effect of the viral RNA presented, stimulating innate immunity through the Toll-like receptor (TLR) 7-dependent pathway.6 We hypothesize that the combined effect of adjuvant activity and the heterogenous mix of flu strains that an individual would be exposed to over the course of multiple seasonal vaccinations may enhance the breadth of antibody response and promote the generation of cross-reactive antibodies.A retrospective case-control study conducted in US military personnel after the outbreak of 2009 pH1N1 showed that both 2008–2009 seasonal influenza vaccine and history of seasonal vaccine in the prior 4 years afforded some protection against pH1N1. Vaccine effectiveness (VE) was high in persons ≥ 40 (55%) or < 25 (50%) years of age but very low in persons 25–39 years of age (< 10%).7 These findings correlate with the high levels of cross-reactive 2009 pH1N1 antibodies reported here, with 30% in the 1960–1965 cohort (age range = 35–48) but only 4% in the 1972–1977 cohort (age range = 23–36). Our findings are similar to the results found recently in an elderly population in the United States.8 The exception is in those individuals born before 1950, in whom antibody responses were much higher in this cohort. Both our study and the US study differ from two recent seroprevalence studies in Singapore and China, where cross-reactive antibodies were rare in various age groups.9,10 High seasonal influenza vaccination rates in US military personnel found here and prior studies11 may explain the differences observed in these populations, although results from small retrospective seroprevalence studies should be interpreted cautiously. Possible alternative explanations include differences in laboratory assay methods, natural influenza exposure in the sampled populations, and/or use of convenience sampling methods.Studies in humans suggest that the antibody to influenza neuraminidase is associated with resistance to influenza.12 A recent serological study in a small number of human serum samples showed that 24% had cross-reactive antibodies to avian N1,13 similar to our findings (22.5%). In addition, we observed that 9% of serum samples had cross-reactive antibodies to pH1N1.Like pH1N1, persons < 40 years old seem to be most affected by H5N1 infection, with infection rarer in older individuals.14 However, we did not find a difference in cross-reactive antibody prevalence to either neuraminidase or neutralizing antibodies (H5pp) with year of birth or other immunologic markers of exposure, including vaccination history or prior respiratory illness.A possible limitation of our study is that the DMSS may not have captured all relevant medical encounter and/or vaccination data, particularly for encounters that were not entered into the system electronically or coded accurately. Data in the DMSS are provider-dependent, and the DMSS captures data from various historical time periods, dating back to 1980 for immunization data, 1985 for Department of Defense Serum Repository specimens, 1990 for demographic data, and only 1996 for outpatient data. Interpretation of data presented on history of respiratory illness, which is entirely dependent on voluntary provider reporting and International Classification of Diseases (ICD-9) coding, is particularly limited by lack of virologic confirmation.Cross-reactive immunity to pathogenic influenza strains was found in a subset of US military service members, and it may serve to prevent or reduce the severity of influenza. A better understanding of the mechanisms underlying the development of cross-reactive antibodies will aid in the development of more effective preventive and therapeutic measures.  相似文献   
9.
Lung ultrasonography for assessment of oxygenation response to prone position ventilation in ARDS     
Malik Haddam  Laurent Zieleskiewicz  Sebastien Perbet  Alice Baldovini  Christophe Guervilly  Charlotte Arbelot  Alexandre Noel  Coralie Vigne  Emmanuelle Hammad  François Antonini  Samuel Lehingue  Eric Peytel  Qin Lu  Belaid Bouhemad  Jean-Louis Golmard  Olivier Langeron  Claude Martin  Laurent Muller  Jean-Jacques Rouby  Jean-Michel Constantin  Laurent Papazian  Marc Leone  CAR’Echo Collaborative Network  AzuRea Collaborative Network 《Intensive care medicine》2016,42(10):1546-1556

Purpose

Prone position (PP) improves oxygenation and outcome of acute respiratory distress syndrome (ARDS) patients with a PaO2/FiO2 ratio <150 mmHg. Regional changes in lung aeration can be assessed by lung ultrasound (LUS). Our aim was to predict the magnitude of oxygenation response after PP using bedside LUS.

Methods

We conducted a prospective multicenter study that included adult patients with severe and moderate ARDS. LUS data were collected at four time points: 1 h before (baseline) and 1 h after turning the patient to PP, 1 h before and 1 h after turning the patient back to the supine position. Regional lung aeration changes and ultrasound reaeration scores were assessed at each time. Overdistension was not assessed.

Results

Fifty-one patients were included. Oxygenation response after PP was not correlated with a specific LUS pattern. The patients with focal and non-focal ARDS showed no difference in global reaeration score. With regard to the entire PP session, the patients with non-focal ARDS had an improved aeration gain in the anterior areas. Oxygenation response was not associated with aeration changes. No difference in PaCO2 change was found according to oxygenation response or lung morphology.

Conclusions

In ARDS patients with a PaO2/FiO2 ratio ≤150 mmHg, bedside LUS cannot predict oxygenation response after the first PP session. At the bedside, LUS enables monitoring of aeration changes during PP.
  相似文献   
10.
Remodelling of vertebral endplate subchondral bone in scoliosis: A micro-CT analysis in a porcine model     
Jean-Michel Laffosse  Franck Accadbled  Nicolas Bonnevialle  A. Gomez-Brouchet  Jérôme Sales de Gauzy  Pascal Swider 《Clinical biomechanics (Bristol, Avon)》2010

Background

Disc degeneration has been correlated with alteration of bone density of adjacent vertebral bodies. Abnormal mechanical loading appears in scoliosis as compared to normal spines. How vertebral endplate was remodelled in scoliosis is not well understood.

Methods

We conducted a micro-CT analysis of subchondral bone of the vertebral endplate at the curve apex in a porcine scoliosis model. Two adjacent thoracic T5T6 and lumbar L1L2 levels were instrumented in six four-week-old pigs with a custom offset implant connected by a flexible stainless steel wire. Two months after implantation, three cylindrical specimens were harvested into the vertebral endplate of each of the scoliosis levels: centre, convexity and concavity, and from the dorsal T9T10 vertebral units obtained from nine three-month-old non-instrumented pigs used as controls. Micro-CT analysis was carried out on each specimen.

Findings

In the concavity of the scoliotic spine, bone volume fraction, trabecular thickness, and trabecular separation significantly increased whereas in the convexity, only trabecular separation increased. Connectivity index and trabecular number decreased significantly.

Interpretation

This was the first micro-CT study of subchondral bone microarchitecture of the scoliotic vertebral end plate. At the curve apex, increased compression in the concavity induced an osteogenic process. In the convexity, diminished compression caused an osteolytic process with a local resorption. Clinically, the unbalanced tissue remodelling could play a role in the convective and diffusive transports into the end plate, which is of prime importance for the segment homeostasis in scoliosis treatment with or without surgery.  相似文献   
1 [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] 下一页 » 末  页»
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号